Source comparison
TB-500 Research Performance: Protocol Comparison
Tissue Regeneration Markers 340% increase vs control (Johns Hopkins study) 180% increase vs control 40–60% increase vs control Immediate administration capitalizes on inflammatory phase when actin dynamics are most malleable Wound Closure Rate 58% faster (Univ
This comparison does not assign a generated winner or score.
- Tissue Regeneration Markers
- 340% increase vs control (Johns Hopkins study)
- 180% increase vs control
- 40–60% increase vs control
- Immediate administration capitalizes on inflammatory phase when actin dynamics are most malleable
- Wound Closure Rate
- 58% faster (University of Sydney)
- 41% faster
- 14% faster
- Therapeutic window closes rapidly; delayed dosing shows minimal benefit
- VEGF Upregulation
- Peak at 48h post-injection
- Peak at 72h post-injection
- Minimal or absent
- Earlier administration aligns VEGF peak with critical angiogenesis window
- Optimal Dose Range
- 4–5mg initial, 2–3mg maintenance
- Higher doses (6–7mg) show no additional benefit
- Mechanism is time-dependent, not dose-dependent beyond threshold
- Administration Route
- Subcutaneous near injury site
- Subcutaneous or intramuscular
- Intramuscular systemic only
- Local delivery outperforms systemic in localized injury models by 40% bioavailability